How Wealthy Joe Made 127%

So – we’ve reached another end to a quarter, and I wanted to update you on how the Wealthy Joe investment fund is doing.

Truth be told, we currently only have two stocks in the fund. But they both have done pretty well!

The fund’s objective is to invest in disruptive innovation. We try to find companies that are innovating and disrupting the way things are currently being done.

Now, when you invest in this type of company, you will have to endure extreme volatility.

Disruptively innovative companies can fall hard during periods of market sell-off. It’s not uncommon for them to fall 20%, 305, or even 50%.

So…what are the two companies we chose?

1. The Trade Desk (NASDAQ: TTD): Performance +328%.

The Trade Desk operates a cloud-based technology platform that lets ad buyers optimize their spending, getting the right ads in front of the right person at the right time.

2. Ziopharm Oncology (NASDAQ: ZIOP): Performance +51%.

Ziopharm is a developmental biotechnology company engaged in the development and commercialization of small molecules and synthetic biology approaches to new cancer therapies.

As you can see, both stocks have been great performers for Wealthy Joe. The Trade Desk has been phenomenal!

I wish I could say that I knew this would happen. But I didn’t.

I learned about these companies a few years ago and liked their stories, so I took a chance.

That’s pretty much my thought process for both purchases.

The reason we publish our returns is so you can follow the progress of a real portfolio and see the ups and downs a portfolio will move over time.

 

My book, The Stock Market is For Everyone, is a short guide for the beginning, inexperienced investor that is easy to understand and can be put into action immediately.

Click the image of the book at left to be taken to its Amazon page.  (Disclosure: As a participant in the Amazon Services LLC Associates Program, I earn a small commission on each sale generated through these links.)

Advertisements

Make 5-6% In 6 Months Guaranteed!

Those of you who have read The Stock Market is For Everyone, and/or regularly follow this blog, might be wondering right about now, “Has Eric been hacked?!” after seeing the title of this post.  Not to worry!  It’s still me.  Read on…

On November 2, 2018, Illumina (NASDAQ: ILMN), the gene-sequencing giant, announced that it would be acquiring its much smaller competitor, Pacific Biosciences of California (NASDAQ: PACB) for $1.2 billion in cash, or $8 a share.  The deal is expected to close in mid-2019.

Currently, PACB is at $7.52, which is 6% below the deal price.  The reason it’s trading below the deal price is that the acquisition is not expected to close for at least five to six months.

The likelihood that this deal would fall apart is slim to none.

Therefore, if you have money sitting around that you can tie up for six months, this opportunity guarantees that you’ll get a return somewhere between 5 and 6% depending on where you buy it.

In my opinion it’s worth it, if you have the money and the time to wait.

Disclaimer/Disclosure Statement: Information in this article is not intended to be a recommendation to invest in any stock.  Rather, it is presented for readers’ education and consideration when making their own investment decisions.  The author has no position in either of the two companies mentioned.

 

My book, The Stock Market is For Everyone, is a short guide for the beginning, inexperienced investor that is easy to understand and can be put into action immediately.

Click the image of the book at left to be taken to its Amazon page.  (Disclosure: As a participant in the Amazon Services LLC Associates Program, I earn a small commission on each sale generated through these links.)